Bioxyne Double-Strikes in LATAM and Europe

SYDNEY – Bioxyne Limited, an international health and life sciences company focused on the manufacturing and distribution of novel medicines, including medical Cannabis, psilocybin, and MDMA, has signed two new commercial agreements – one stretching into Latin America, the other deepening a European foothold.

Bioxyne’s wholly-owned subsidiary Breathe Life Sciences (BLS) has executed an expanded supply agreement with Remidose LATAM SRL to include the supply of three Cannabis flower SKUs to Costa Rica, representing the first international supply of medical Cannabis flower into the country’s regulated market. The initial delivery, expected before the end of June 2026, carries an invoice value above $500,000. The deal also covers future supply of pastilles to Costa Rica and Panama.

Remidose Managing Director Michael Mayne noted strong early demand signals, with indications that initial stock could be committed quickly. Bioxyne CEO Sam Watson highlighted the speed of progress once a market presence is secured, describing Costa Rica as a foundation for wider regional growth as regulations develop.

On the European front, Bioxyne secured a two-year supply agreement valued at up to $50 million with German pharmaceutical firm ADREXpharma GmbH. The deal includes a $25 million minimum purchase commitment in the first 12 months and provides for automatic renewal. The expanded contract builds on an initial supply arrangement signed in June 2025, which committed Farmakem and Adrex to purchase and distribute a minimum of 1,600 kilograms of GMP-manufactured medical Cannabis flower and finished product, with the first delivery of 580 kg scheduled for September and a second shipment in November.

The German medical Cannabis market is experiencing rapid growth following regulatory changes in early 2025, with expectations it will surpass Australia’s A$1 billion medical Cannabis market in 2026. For Bioxyne, that timing is deliberate. Fourteen Australian-manufactured Cannabis strains produced by BLS have been registered with Germany’s Federal Institute for Drugs and Medical Devices (BfArM), authorizing their importation and sale within the German market.

Costa Rica, by contrast, is an early-stage bet. The country officially launched its medical Cannabis rollout in June 2025, making Bioxyne’s timing aggressive by design – planting a distribution anchor before competition consolidates.

What’s worth noting is the structural logic connecting both deals. Bioxyne is not chasing volume alone. It is assembling a branded, GMP-certified export system across two very different regulatory environments simultaneously. Germany promises scale and defined commercial returns, whereas Costa Rica and Panama offer first-mover positioning in markets that are still writing their rulebooks.